摘要
目的:探讨参附注射液治疗急性心源性休克的临床疗效。方法:26例急性心源性休克患者随机分为两组:对照组12例和治疗组14例。对照组采用内科常规治疗;治疗组在对照组治疗的基础上加用参附注射液治疗。并观察两组用药2h后心率、血压、末梢血氧含量及心脏功能变化。结果:治疗组治疗后心率为(90±17)次/min明显低于对照组(106±19)次/min(P<0.05),治疗组治疗后血压为(13.6±2.3/9.2±1.5)kPa,对照组治疗后血压为(10.6±1.3/8.2±0.5)kPa,两组比较,有显著性差异(P<0.05),治疗组治疗后收缩末期容积、舒张末期容积和射血分数与对照组比较,有显著性差异(P<0.05)。结论:参附注射液是治疗心源性休克安全、有效的药物。
Objective： To study the therapeutic efficacy of Shenfu injection in acute cardiogenic shock. Methods.Twenty-six cases of acute cardiogenic shock were divided into tow groups randomly：12 cases in control group were solely given routine treatment, 14 cases in observation group were given routine treatment combined with Shenfu injection. The heart rate, blood pressure, blood oxygen content and heart function were respectively observed in each group. Results： By using shenfu injection for 2 hours, the blood pressure of the patients of observation group was increase and stable, heart rate was decrease and heart function was improved. Conclution：Shenfu injection is an effective and safe drug for treatment of acute cardiogenic shock.
出处
《实用临床医学（江西）》
CAS
2005年第9期32-34,共3页
Practical Clinical Medicine
关键词
心源性休克
参附注射液
血压
心功能
acute cardiogenic shock
shenfu injection
blood pressure
heart function
